Fierce Healthcare Names SpotitEarly a “Fierce 15” Company of 2026

The Company’s Appearance on the Prestigious List Denotes Its Innovative Approach and Role in Moving Multi-Cancer Early Detection Screening Forward

ENGLEWOOD, N.J.--(BUSINESS WIRE)--SpotitEarly, a multi-cancer early detection startup that uses AI and trained canines to identify cancer odor signatures in breath samples, today announced that Fierce Healthcare has named it as one of 2026’s “Fierce 15” healthcare companies. The publication’s special report features the most innovative private healthcare companies looking to change the face of the industry.

"Over the past eight years, we have reviewed hundreds of private companies for potential inclusion in the 'Fierce 15' special report. The selection draws from diverse sectors across the industry, from primary care to health technology. Year after year, these honorees remind us that the future of healthcare is being built right now, and this special report is our way of showcasing their innovative work and honoring their impact," said Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare.

Focused on addressing the barriers to early cancer screening, SpotitEarly continued developing its Bio-AI Hybrid platform, LUCID, across four major cancer types (breast, colorectal, lung, and prostate) since entering the U.S. market in May 2025, positioning the company as a growing force in multi-cancer early cancer detection.

In the past year, SpotitEarly has partnered with leading New Jersey health system Hackensack Meridian Health to launch the PINK Study, a 2,000-participant, multicenter, double-blind observational study focused on breast cancer detection in women undergoing standard-of-care mammography or biopsy. The company has also signed a research collaboration agreement with Temple University’s Fox Chase Cancer Center, focused on lung cancer.

These collaborations build on a peer-reviewed clinical foundation, including the prospective, double-blind Rainbow Study, which reported 93.9% sensitivity and 94.3% specificity across four cancer types, published in Scientific Reports by the Nature Publishing Group.

“We built SpotitEarly around a simple idea: that early cancer detection should be accessible, affordable, and backed by real clinical evidence,” says Shlomi Madar, CEO of SpotitEarly. “Being named a Fierce 15 company tells us that the scientific and healthcare communities are paying attention to what our data is showing. With cancer rates rising, especially among younger populations, we’re focused on building partnerships and the evidence base that will bring this technology to the people who need it.”

To learn more about SpotitEarly and its technology, please visit https://www.spotitearly.com.

About Fierce Healthcare

Fierce Healthcare delivers healthcare news at the intersection of business and policy. Our journalists strive to bring our readers breaking industry news, exclusive interviews and thoughtfully-reported stories that offer a deeper insight on how changes in the industry impact their corner of the healthcare world. Our family includes Fierce Healthcare, Fierce Health Payer, Fierce Health Tech, Fierce Hospitals and Fierce Health Finance. Click here to subscribe to one or all of our newsletters.

About SpotitEarly

SpotitEarly aims to revolutionize cancer screening with its breath-based early detection test for multiple types of cancer. Powered by LUCID, a proprietary bio-AI hybrid platform, the test will integrate advanced artificial intelligence with nature's unparalleled detection abilities to identify cancer-associated volatile organic compounds (VOCs) at early stages. By combining AI with the scent-based biometrics of trained canines, SpotitEarly will introduce a simple breath collection process involving a face mask kit. A diverse, multidisciplinary team of medical professionals, scientists, and technology experts collaborate seamlessly to bring this innovative solution to life. Subject to regulatory approval, SpotitEarly aims to improve access to cancer screening, enhance early detection rates, and significantly boost survival outcomes. For more information, visit our website or follow SpotitEarly on LinkedIn, Facebook, and Instagram.